ABION Inc.
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
203400 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시
- Website:
- https://abionbio.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
ABION Inc. is a clinical-stage biopharmaceutical company pioneering the development of innovative, first-in-class and best-in-class therapeutics. The company's research and development efforts are primarily focused on oncology and viral infectious diseases. Its lead oncology candidate, ABN401, is a targeted c-Met tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) that has demonstrated a superior safety profile in clinical trials. The pipeline also includes ABN501, a novel Claudin-3 targeting monoclonal antibody for various cancers. In its infectious disease program, ABION is developing ABN101, a second-generation Interferon-β inhaler as a broad-spectrum anti-viral therapy for respiratory infections. The company aims to address significant unmet medical needs through internationally recognized clinical processes for eventual global commercialization.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ABION Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ABION Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
